IVD Market is estimated to increase at a growth rate of 5.1% CAGR over the forecast period from 2024 to 2030.
The global IVD Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product and Services (Reagents & Kits, Services, Instruments, Data Management Software), By Application (Infectious diseases, Diabetes, Drug Testing/ Pharmacogenomics, Autoimmune diseases, Oncology, Cardiology, HIV/AIDS, Nephrology, Others), By Technology (Immunoassay/ Immunochemistry, Clinical chemistry, Hematology, Molecular diagnostics, Microbiology, Coagulation and Hemostasis, Urinalysis, Others), By End-User (Hospital laboratories, Point-of-care testing centers, Academic institutes, Clinical laboratories, Patients, Others).
An Introduction to IVD Market in 2024
The In Vitro Diagnostics (IVD) Market encompasses a wide range of medical devices, instruments, reagents, and assays used for diagnosing diseases, infections, and medical conditions outside the human body. This market includes clinical chemistry analyzers, immunoassay systems, molecular diagnostics, hematology analyzers, point-of-care testing devices, and microbiology testing equipment. IVD plays a crucial role in healthcare by providing rapid, accurate, and actionable diagnostic information for patient care, disease management, and public health surveillance. Innovations in the IVD market focus on automation, miniaturization, connectivity, multiplexing, and artificial intelligence applications, driving advancements in personalized medicine, precision diagnostics, and healthcare efficiency.
IVD Market Competitive Landscape
The global IVD Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, IVD Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the IVD Industry include- Abbott Laboratories, Accelerate Diagnostics Inc, Agilent Technologies Inc, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Caris Life Sciences Inc, Chembio Diagnostics Inc , Danaher Corp, Devyser, DiaSorin S.p.A, GENSPEED Biotech GmbH, Hologic Inc, Illumina Inc, Menarini Silicon Biosystems, Merck KGaA, PerkinElmer Inc, QIAGEN N.V., Quidel Corp, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, SpeeDx Pty. Ltd, Surmodics Inc, Sysmex Corp, Thermo Fisher Scientific Inc.
IVD (In Vitro Diagnostics) Market Trend: Shift Towards Personalized Medicine and Companion Diagnostics
A significant trend in the market for in vitro diagnostics (IVD) is the shift towards personalized medicine and companion diagnostics, driven by advances in genomics, molecular biology, and precision medicine. Personalized medicine aims to tailor medical treatments to the individual characteristics of each patient, including their genetic makeup, biomarker profiles, and disease susceptibility. Companion diagnostics play a crucial role in personalized medicine by providing information about a patient's likelihood of responding to a specific treatment or experiencing adverse reactions. This trend encompasses the development of innovative IVD assays, platforms, and algorithms that enable the identification of biomarkers, genetic mutations, and other molecular signatures associated with disease prognosis, treatment response, and therapeutic decision-making. As healthcare providers increasingly adopt personalized medicine approaches to optimize patient care and treatment outcomes, there is growing demand for advanced IVD technologies that support precision diagnostics and targeted therapies across diverse medical specialties, including oncology, infectious diseases, and chronic conditions.
IVD (In Vitro Diagnostics) Market Driver: Growing Burden of Chronic Diseases and Infectious Outbreaks
The primary driver of the IVD market is the growing burden of chronic diseases and infectious outbreaks worldwide, highlighting the need for rapid, accurate, and reliable diagnostic tests to support disease prevention, early detection, and treatment monitoring. Chronic diseases, such as cancer, cardiovascular disorders, diabetes, and autoimmune conditions, represent a significant and increasing healthcare challenge globally, contributing to rising healthcare costs, morbidity, and mortality. Additionally, infectious disease outbreaks, including the COVID-19 pandemic, highlight the critical role of IVD tests in pandemic preparedness, surveillance, and response efforts. As healthcare systems strive to address the complex challenges posed by chronic diseases and emerging infectious threats, there is escalating demand for IVD solutions that offer high sensitivity, specificity, and multiplexing capabilities for the timely and effective diagnosis of diseases, enabling prompt interventions, targeted therapies, and improved patient outcomes.
IVD (In Vitro Diagnostics) Market Opportunity: Integration of Artificial Intelligence and Digital Health Solutions
An opportunity in the IVD market lies in the integration of artificial intelligence (AI) and digital health solutions to enhance diagnostic accuracy, efficiency, and accessibility, while driving innovation and value in healthcare delivery. AI algorithms and machine learning models can analyze large volumes of clinical data, imaging studies, and molecular profiles to identify patterns, predict disease risk, and optimize diagnostic workflows in real-time. Digital health solutions, such as telemedicine platforms, mobile applications, and cloud-based analytics, enable remote access to diagnostic testing services, patient monitoring, and healthcare provider collaboration, facilitating timely interventions and continuity of care. By harnessing the power of AI and digital health technologies, stakeholders in the IVD market can improve diagnostic capabilities, streamline clinical decision-making, and empower patients to take an active role in managing their health, ultimately advancing the delivery of personalized medicine and precision diagnostics across healthcare settings.
IVD Market Share Analysis: Molecular Diagnostics is the fastest growing market segment over the forecast period to 2030
Among the diverse array of products and services within the In Vitro Diagnostics (IVD) sector, Molecular Diagnostics stands out as the fastest-growing segment. Molecular Diagnostics involves the analysis of biological markers in genetic material (DNA and RNA) to detect genetic variations or microbial infections. This segment encompasses various technologies such as polymerase chain reaction (PCR), nucleic acid sequencing, and microarrays, among others. The rapid growth of Molecular Diagnostics can be attributed to several factors. Firstly, advancements in technology have led to the development of highly sensitive and specific molecular assays, allowing for the detection of pathogens with greater accuracy and speed. Additionally, the increasing demand for personalized medicine and targeted therapies has driven the adoption of molecular testing in the diagnosis and monitoring of diseases such as cancer, infectious diseases, and genetic disorders. Furthermore, the COVID-19 pandemic has underscored the importance of molecular diagnostics in infectious disease management, leading to a surge in demand for molecular testing platforms and assays. As healthcare systems worldwide continue to prioritize early disease detection, precision medicine, and infectious disease surveillance, the Molecular Diagnostics segment is expected to sustain its rapid growth trajectory in the IVD market.
IVD Market Segmentation
By Product and Service
Reagents & Kits
Services
Instruments
Data Management Software
By Application
Infectious diseases
Diabetes
Drug Testing/ Pharmacogenomics
Autoimmune diseases
Oncology
Cardiology
HIV/AIDS
Nephrology
Others
By Technology
Immunoassay/ Immunochemistry
Clinical chemistry
Hematology
Molecular diagnostics
Microbiology
Coagulation and Hemostasis
Urinalysis
Others
By End-User
Hospital laboratories
Point-of-care testing centers
Academic institutes
Clinical laboratories
Patients
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
IVD Companies
Abbott Laboratories
Accelerate Diagnostics Inc
Agilent Technologies Inc
Becton, Dickinson and Company
bioMérieux SA
Bio-Rad Laboratories Inc
Caris Life Sciences Inc
Chembio Diagnostics Inc
Danaher Corp
Devyser
DiaSorin S.p.A
GENSPEED Biotech GmbH
Hologic Inc
Illumina Inc
Menarini Silicon Biosystems
Merck KGaA
PerkinElmer Inc
QIAGEN N.V.
Quidel Corp
F. Hoffmann-La Roche Ltd
Siemens Healthineers AG
SpeeDx Pty. Ltd
Surmodics Inc
Sysmex Corp
Thermo Fisher Scientific Inc
* List not Exhaustive
Reasons to Buy the IVD Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the IVD Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the IVD Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 IVD Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global IVD Market Size Outlook, $ Million, 2021 to 2030
3.2 IVD Market Outlook by Type, $ Million, 2021 to 2030
3.3 IVD Market Outlook by Product, $ Million, 2021 to 2030
3.4 IVD Market Outlook by Application, $ Million, 2021 to 2030
3.5 IVD Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of IVD Industry
4.2 Key Market Trends in IVD Industry
4.3 Potential Opportunities in IVD Industry
4.4 Key Challenges in IVD Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global IVD Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global IVD Market Outlook by Segments
7.1 IVD Market Outlook by Segments, $ Million, 2021- 2030
By Product and Service
Reagents & Kits
Services
Instruments
Data Management Software
By Application
Infectious diseases
Diabetes
Drug Testing/ Pharmacogenomics
Autoimmune diseases
Oncology
Cardiology
HIV/AIDS
Nephrology
Others
By Technology
Immunoassay/ Immunochemistry
Clinical chemistry
Hematology
Molecular diagnostics
Microbiology
Coagulation and Hemostasis
Urinalysis
Others
By End-User
Hospital laboratories
Point-of-care testing centers
Academic institutes
Clinical laboratories
Patients
Others
8 North America IVD Market Analysis and Outlook To 2030
8.1 Introduction to North America IVD Markets in 2024
8.2 North America IVD Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America IVD Market size Outlook by Segments, 2021-2030
By Product and Service
Reagents & Kits
Services
Instruments
Data Management Software
By Application
Infectious diseases
Diabetes
Drug Testing/ Pharmacogenomics
Autoimmune diseases
Oncology
Cardiology
HIV/AIDS
Nephrology
Others
By Technology
Immunoassay/ Immunochemistry
Clinical chemistry
Hematology
Molecular diagnostics
Microbiology
Coagulation and Hemostasis
Urinalysis
Others
By End-User
Hospital laboratories
Point-of-care testing centers
Academic institutes
Clinical laboratories
Patients
Others
9 Europe IVD Market Analysis and Outlook To 2030
9.1 Introduction to Europe IVD Markets in 2024
9.2 Europe IVD Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe IVD Market Size Outlook by Segments, 2021-2030
By Product and Service
Reagents & Kits
Services
Instruments
Data Management Software
By Application
Infectious diseases
Diabetes
Drug Testing/ Pharmacogenomics
Autoimmune diseases
Oncology
Cardiology
HIV/AIDS
Nephrology
Others
By Technology
Immunoassay/ Immunochemistry
Clinical chemistry
Hematology
Molecular diagnostics
Microbiology
Coagulation and Hemostasis
Urinalysis
Others
By End-User
Hospital laboratories
Point-of-care testing centers
Academic institutes
Clinical laboratories
Patients
Others
10 Asia Pacific IVD Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific IVD Markets in 2024
10.2 Asia Pacific IVD Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific IVD Market size Outlook by Segments, 2021-2030
By Product and Service
Reagents & Kits
Services
Instruments
Data Management Software
By Application
Infectious diseases
Diabetes
Drug Testing/ Pharmacogenomics
Autoimmune diseases
Oncology
Cardiology
HIV/AIDS
Nephrology
Others
By Technology
Immunoassay/ Immunochemistry
Clinical chemistry
Hematology
Molecular diagnostics
Microbiology
Coagulation and Hemostasis
Urinalysis
Others
By End-User
Hospital laboratories
Point-of-care testing centers
Academic institutes
Clinical laboratories
Patients
Others
11 South America IVD Market Analysis and Outlook To 2030
11.1 Introduction to South America IVD Markets in 2024
11.2 South America IVD Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America IVD Market size Outlook by Segments, 2021-2030
By Product and Service
Reagents & Kits
Services
Instruments
Data Management Software
By Application
Infectious diseases
Diabetes
Drug Testing/ Pharmacogenomics
Autoimmune diseases
Oncology
Cardiology
HIV/AIDS
Nephrology
Others
By Technology
Immunoassay/ Immunochemistry
Clinical chemistry
Hematology
Molecular diagnostics
Microbiology
Coagulation and Hemostasis
Urinalysis
Others
By End-User
Hospital laboratories
Point-of-care testing centers
Academic institutes
Clinical laboratories
Patients
Others
12 Middle East and Africa IVD Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa IVD Markets in 2024
12.2 Middle East and Africa IVD Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa IVD Market size Outlook by Segments, 2021-2030
By Product and Service
Reagents & Kits
Services
Instruments
Data Management Software
By Application
Infectious diseases
Diabetes
Drug Testing/ Pharmacogenomics
Autoimmune diseases
Oncology
Cardiology
HIV/AIDS
Nephrology
Others
By Technology
Immunoassay/ Immunochemistry
Clinical chemistry
Hematology
Molecular diagnostics
Microbiology
Coagulation and Hemostasis
Urinalysis
Others
By End-User
Hospital laboratories
Point-of-care testing centers
Academic institutes
Clinical laboratories
Patients
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Accelerate Diagnostics Inc
Agilent Technologies Inc
Becton, Dickinson and Company
bioMérieux SA
Bio-Rad Laboratories Inc
Caris Life Sciences Inc
Chembio Diagnostics Inc
Danaher Corp
Devyser
DiaSorin S.p.A
GENSPEED Biotech GmbH
Hologic Inc
Illumina Inc
Menarini Silicon Biosystems
Merck KGaA
PerkinElmer Inc
QIAGEN N.V.
Quidel Corp
F. Hoffmann-La Roche Ltd
Siemens Healthineers AG
SpeeDx Pty. Ltd
Surmodics Inc
Sysmex Corp
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
